Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada-Reference-Cited by-同舟云学术

Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada

Published:2021-07 Issue: Volume:157 Page:40-47
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Debieuvre Didier^ORCID,Juergens Rosalyn A.,Asselain Bernard,Audigier-Valette Clarisse^ORCID,Auliac Jean-Bernard,Barlesi Fabrice,Benoit Nicolas,Bombaron Pierre,Butts Charles A.,Dixmier Adrien,Gröschel Andreas,Gutz Sylvia,Labbé Catherine,Moro-Sibilot Denis,Pérol Maurice^ORCID,Raspaud Christophe,Schumann Christian,Juarez-Garcia Ariadna,Lakhdari Khalid,Pettersson Filippa,Penrod John R.,Reynaud Dorothee,Waldenberger Daniela,Allan Victoria^ORCID,Sebastian Martin^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

5. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis;Antonia;Lancet Oncol.,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;CLIN LUNG CANCER;2024

2. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;Clinical Lung Cancer;2024-09

3. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

4. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review);International Journal of Oncology;2024-02-13

5. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021;ESMO Open;2024-02